Peter Olagunju - Dec 1, 2022 Form 4 Insider Report for TCR2 THERAPEUTICS INC. (TCRR)

Role
Chief Technical Officer
Signature
Margaret Siegel as Attorney-In-Fact
Stock symbol
TCRR
Transactions as of
Dec 1, 2022
Transactions value $
-$1,766
Form type
4
Date filed
12/5/2022, 06:50 PM
Previous filing
Nov 18, 2022
Next filing
Dec 7, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TCRR Common Stock Options Exercise +33.4K +1524.13% 35.6K Dec 1, 2022 Direct F1, F2
transaction TCRR Common Stock Sale -$1.77K -1.27K -3.58% $1.39 34.3K Dec 2, 2022 Direct F3
holding TCRR Common Stock 2.19K Dec 1, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TCRR Restricted Stock Unit Options Exercise $0 +33.4K +116.66% $0.00 62K Dec 1, 2022 Common Stock 33.4K Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the the aggregate number of common stock converted from restricted stock units granted to the reporting person on 11/17/2022 pursuant to the issuer's offer to exchange eligible options for new restricted stock units program.
F2 Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration.
F3 The sales reported represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.
F4 35% of these restricted stock units vested on December 1, 2022, 25% will vest on each of December 1, 2023 and December 1, 2024, and the remaining 15% will vest on December 1, 2025.